Rosiglitazone: Can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approaches

BMC Research Notes

Volumn 2, Issue , 2009, Pages

  Friedrich, Jan O ^a,b,c   Beyene, Joseph ^b,d   Adhikari, Neill Kj ^b,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e Sunnybrook Health Sciences Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 66749120269     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-2-5     Document Type: Article

References (27)

1. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. SE Nissen K Wolski, N Engl J Med 2007 356 2457 2471 [ Erratum. N Engl J Med 2007, 357 : 100.] 10.1056/NEJMoa072761 17517853 (Pubitemid 46919772)
2. Uncertain effects of rosiglitazone on the risk of myocardial infarction and cardiovascular death. GA Diamond L Bax S Kaul, Ann Intern Med 2007 147 578 581 17679700
3. Rosiglitazone: seeking a balanced perspective. Anonymous, Lancet 2007 369 9576 1834 17544746
4. The rosiglitazone story - lessons from an FDA advisory committee meeting. CJ Rosen, N Engl J Med 2007 357 844 846 10.1056/NEJMp078167 17687124
5. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. PD Home SJ Pocock H Beck-Nielsen R Gomis M Hanefeld NP Jones M Komajda JJV McMurray for the RECORD Study Group, N Engl J Med 2007 357 28 38 10.1056/NEJMoa073394 17551159
6. Rosiglitazone for type 2 diabetes mellitus. B Richter E Bandiera-Echtler K Bergerhoff C Clar S Ebrahim, Cochrane Database Syst Rev 2007 3 D006063 17636824
7. FDA Briefing Document: joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. July 30, 2007. Division of Metabolism and Endocrine Products and Office of Surveillance and Epidemiology, US Food and Drug Administration, http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4308b1-02- fda-backgrounder.pdf and http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007- 4308b1-01-sponsor-backgrounder.pdf
8. Study No. ZM2005/00181/01, Avandia Cardiovascular Event Modeling Project, and study No. HM2006/00497/00WEUSRTP866, Coronary Heart Disease Outcomes in Patients Receiving Antidiabetic Agents. GlaxoSmithKline clinical trial register, http://ctr.gsk.co.uk/Summary/Rosiglitazone/III-CVmodeling.pdf
9. Long-term risk of cardiovascular events with rosiglitazone. A meta-analysis. S Singh YK Loke CD Furberg, JAMA 2007 298 1189 1195 10.1001/jama.298.10.1189 17848653
10. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. RM Lago PP Singh RW Nesto, Lancet 2007 370 1129 1136 10.1016/S0140-6736(07)61514-1 17905165
11. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. MJ Sweeting AJ Sutton PC Lambert, Stat Med 2004 23 1351 1375 [ Erratum. Stat Med 2006, 25 :2700.] 10.1002/sim.1761 15116347
12. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. MJ Bradburn JJ Deeks JA Berlin A Russell Localio, Stat Med 2007 26 53 77 10.1002/sim.2528 16596572
13. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. JO Friedrich NKJ Adhikari J Beyene, BMC Med Res Methodol 2007 7 5 17244367 10.1186/1471-2288-7-5 (Pubitemid 46169611)
14. GlaxoSmithKline trial register. http://ctr.gsk.co.uk/Summary/ rosiglitazone/studylist.asp
15. Rosiglitazone and cardiovascular risk. MB Bracken, N Engl J Med 2007 357 937 938 10.1056/NEJMc071602 17761600
16. Rosiglitazone and cardiovascular risk. GA Diamond S Kaul, N Engl J Med 2007 357 938 939 17806135
17. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. SE Kahn SM Haffner MA Heise WH Herman RR Holman NP Jones BG Kravitz JM Lachin MC O'Neill B Zinman G Viberti for the ADOPT Study Group, N Engl J Med 2006 355 2427 2443 10.1056/NEJMoa066224 17145742
18. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. HC Gerstein S Yusuf RR Holman J Bosch Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication Trial Investigators, Lancet 2006 368 1096 1105 10.1016/S0140-6736(06)69829-2 16997664
19. A randomized, placbo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. HJ Dargie PR Hilderbrandt GA Riegger JJV McMurray SO McMorn JN Roberts A Zambanini JPH Wilding, J Am Coll Cardiol 2007 49 1696 1704 http://ctr.gsk.co.uk/Summary/rosiglitazone/IV-49653-211.pdf Also GlaxoSmithKline clinical trial register: study no. 49653/211. 10.1016/j.jacc.2006.10.077 17448371
20. Large trials versus meta-analyses of smaller trials: How do their results compare? JC Cappelleri JPA Ioannidis CH Schmid SD de Ferranti M Aubert TC Chalmers J Lau, JAMA 1996 276 1332 1338 10.1001/jama.276.16.1332 8861993
21. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. LL Lipscombe T Gomes LE Levesque JE Hux DN Juurlink DA Alter, JAMA 2007 298 2634 2643 10.1001/jama.298.22.2634 18073359
22. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. A meta-analysis of randomized trials. AM Lincoff K Wolski SJ Nicholls SE Nissen, JAMA 2007 298 1180 1188 10.1001/jama.298.10.1180 17848652
23. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. JA Dormandy B Charbonnel DJA Eckland E Erdmann M Massi-Benedetti IK Moules AM Skene MH Tan PJ Lefebvre GD Murray E Standl RG Wilcox L Wilhelmsen J Betteridge K Birkeland A Golay RJ Heine L Koranyi M Laakso M Mokan A Norkus V Pirags T Podar A Scheen W Scherbaum G Schernthaner O Schmitz J Skrha U Smith J Taton on behalf of the PROactive investigators, Lancet 2005 366 1279 1289 10.1016/S0140-6736(05)67528-9 16214598
24. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. WC Winkelmayer S Setoguchi R Levin DH Solomon, Arch Intern Med 2008 168 2368 2375 10.1001/archinte.168.21. 2368 19029503
25. Medical Management of Hyperglycemia in Type 2 Diabetes: a Consensus Algorithm for the Initiation and Adjustment of Therapy. DM Nathan JB Buse MB Davidson E Ferrannini RR Holman R Sherwin B Zinman, Diabetes Care 2009 32 193 203 10.2337/dc08-9025 18945920
26. Thiazolidinediones and cardiovascular outcomes in type 2 diabetes. S Singh CD Furberg, Heart 2009 95 1 3 10.1136/hrt.2008.155507 18753156
27. Thiazolidinediones and heart failure: a teleo-analysis. S Singh YK Loke CD Furberg, Diabetes Care 2007 30 2148 2153 10.2337/dc07-0141 17536074